The 36-month beta value for EVO is also noteworthy at 1.67. There are mixed opinions on the stock, with 1 analysts rating it as a “buy”, 4 rating it as “overweight”, 1 rating it as “hold”, and 0 rating it as “sell”.
The public float for EVO is 336.82M, and at present, short sellers hold a 0.23% of that float. The average trading volume of EVO on July 04, 2025 was 137.29K shares.
EVO stock’s latest price update
The stock of Evotec SE ADR (NASDAQ: EVO) has decreased by -3.23% when compared to last closing price of $4.34.Despite this, the company has seen a loss of -0.47% in its stock price over the last five trading days. accessnewswire.com reported 2025-06-25 that NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury (“AKI”) patients, developed as part of a research consortium led by Kidney Research UK The study focuses on 3 clearly defined cohorts: AKI of iatrogenic origin (following cardiac surgery), AKI to chronic kidney disease (“CKD”) transition and pediatric AKI. This partnership will enable Evotec to understand human disease progression on a molecular level and to perform targeted drug discovery in the field of AKI.
EVO’s Market Performance
Evotec SE ADR (EVO) has experienced a -0.47% fall in stock performance for the past week, with a 4.22% rise in the past month, and a 30.03% rise in the past quarter. The volatility ratio for the week is 3.16%, and the volatility levels for the past 30 days are at 2.72% for EVO. The simple moving average for the past 20 days is 1.76% for EVO’s stock, with a 3.95% simple moving average for the past 200 days.
Analysts’ Opinion of EVO
Morgan Stanley gave a rating of “Equal-Weight” to EVO, setting the target price at $6 in the report published on July 29th of the previous year.
EVO Trading at 1.79% from the 50-Day Moving Average
After a stumble in the market that brought EVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.54% of loss for the given period.
Volatility was left at 2.72%, however, over the last 30 days, the volatility rate increased by 3.16%, as shares surge +2.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.79% upper at present.
During the last 5 trading sessions, EVO fell by -0.47%, which changed the moving average for the period of 200-days by +18.64% in comparison to the 20-day moving average, which settled at $4.13. In addition, Evotec SE ADR saw -13.58% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
N/A, the N/A of Evotec SE ADR, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for EVO
Current profitability levels for the company are sitting at:
- -0.18% for the present operating margin
- 0.14% for the gross margin
The net margin for Evotec SE ADR stands at -0.26%. The total capital return value is set at -0.09%. Equity return is now at value -20.41%, with -9.92% for asset returns.
Currently, EBITDA for the company is -80.66 million with net debt to EBITDA at 1.91. When we switch over and look at the enterprise to sales, we see a ratio of 1.25. The receivables turnover for the company is 3.12for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.03.
Conclusion
In summary, Evotec SE ADR (EVO) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
